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Abstract 2@,2@-Difluorodeoxycytidine (gemcitabine) is
a cytidine analogue with established antitumor activity
against several experimental tumor types and against
human ovarian and non-small-cell lung cancer. Both
preclinical studies and most clinical trials involving
patients with solid tumors have focused on short-term
administration schedules; however, mechanistic studies
indicate that a continuous-infusion schedule may be
more effective. We determined the maximal tolerated
dose (MTD) of gemcitabine in mice using various
schedules. At these MTDs we observed considerably
better antitumor activity of gemcitabine in two of three
murine colon carcinoma lines using a prolonged ad-
ministration as compared with a standard bolus proto-
col (i.p. 120 mg/kg q3d]4). On the latter schedule,
Colon 26—10 grown in BALB/c mice was the most
sensitive tumor line, showing a growth-delay factor
(GDF, number of doubling times gained by the treat-
ment) of 6.7, whereas Colon 38 (grown in C57/B16
mice) was the least sensitive tumor, displaying a GDF
of 0.9. Prolonged treatment (q3d]6) of Colon 26—10 at
a lower dose (100 mg/kg) enhanced the antitumor ac-
tivity (GDF 9.6) while producing similar toxicity.
A similar weight loss was found following the continu-
ous infusion (c.i.) of gemcitabine using Alzet osmotic
pumps s.c. for 3 or 7 days (2 mg/kg), but the GDF
increased to 2.4 in Colon 38 (C57/B16) as compared
with that provided by the bolus injections. Continuous
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infusion of gemcitabine at 15 mg/kg per 24 h q7d]2
i.v. via the tail vein was more effective than bolus
injection against Colon 26—10, with the GDF being
’17.7 and 73% of the tumors regressing completely.
However, against Colon 38 tumors this schedule was
not effective (GDF 0.4), even with a 25% higher dose.
The plasma pharmacokinetics of gemcitabine was de-
termined after one bolus dose (120 mg/kg). The peak
concentration of gemcitabine was 225 lM and that of
the deaminated catabolite 2@,2@-difluorodeoxyuridine
(dFdU) was 79 lM. The elimination of gemcitabine
was much faster than that of dFdU, with the
t
1@2ß
values being 15 min and 8 h, respectively. For the
c.i. schedules, plasma concentrations were below the
detection limit of the assay ( 0.5 lM). Our results
suggest that prolonged infusion of gemcitabine can give
a better antitumor activity than bolus injections and
shows promise of being active in clinical trials.
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Introduction
2@,2@-Difluorodeoxycytidine (gemcitabine) is a cytidine
analogue that has shown marked activity not only
against experimental solid tumors in mice [5, 6, 13] but
also against ovarian and non-small-cell lung cancer in
patients [1, 14, 17]. For treatment of tumor-bearing
animals as well as patients, most schedules have thus
far been limited to bolus injections given at different
doses and intervals. In clinical trials involving patients
with solid tumors the drug was given as a 30-min
infusion, weekly times 3, every 4 weeks, at doses
varying from 800 to 1,250 mg/m2 [14, 17]. However, in
leukemic blast cells, Grunewald et al. [10, 11] observed
a 4-fold higher accumulation of the active triphos-
phate of gemcitabine, 2@,2@-difluorodeoxycytidine
915-1
triphosphate (dFdCTP), when the infusion time was
prolonged. Other antimetabolites such as methot-
rexate, 6-mercaptopurine, and 1-ß-D-arabinofuranosyl-
cytosine, which are commonly used in leukemia, were
more active when given by continuous infusion than
when given by bolus injection [2, 12, 18, 23]. Also 5-
fluorouracil (5-FU) has a better antitumor effect when
given continuously over a longer period [9, 16, 22].
These data are in agreement with the in vitro sensitivity
pattern reported for these drugs [7, 30], in which con-
tinuous exposure (24—72 h) yielded considerably lower
50% inhibitory concentrations (IC
50
values) than did
short-term exposure (1—4 h). For gemcitabine we also
observed that the IC
50
values decreased considerably
at longer exposure times (24—72 h) in ovarian and head
and neck squamous-cell carcinoma cell lines as well
as colon-cancer cell lines [26]. Therefore, we performed
a study to determine whether we could improve
the antitumor activity of gemcitabine by using
prolonged administration and continuous infusion.
For that purpose we used a tumor type that is rather
insensitive to gemcitabine given as a bolus, murine
colon cancer.
Materials and methods
Materials
Gemcitabine and 2@,2@-difluorodeoxyuridine (dFdU) were kindly
provided by Lilly Research Center Ltd. (Indianapolis, Ind., USA).
An ampoule contained gemcitabine HCl equivalent to 500 mg gem-
citabine, 500 mg mannitol, and 80 mg sodium acetate. The gem-
citabine powder was dissolved in 0.9% NaCl to reach a final concen-
tration of 12 mg/ml. Hypnorm anesthetic was obtained from Janssen
Pharmaceutica (Tilburg, The Netherlands). Deoxycytidine (CdR)
was purchased from Sigma Chemical Co. (St. Louis, Mo., USA). All
other chemicals were of analytical grade and were commercially
available.
Tumors
The sources and characteristics of the murine Colon 26 and Colon
38 (adeno) carcinomas have been described elsewhere [20]. The
Colon 26—10 tumor was established by injecting 3—5]106 C26—10
cells into both flanks of BALB/c mice. The C26—10 cells were derived
from a Colon 26 tumor and provided by Dr. W.D. Klohs (Ann
Arbor, Mich., USA) [15, 21]. The resulting tumor line, Colon 26—10,
was significantly different from the original Colon 26 tumor line in,
e.g., its enhanced sensitivity to 5-FU [31, 32]. Moreover, Colon
26—10 tumors did not cause cachexia, in contrast to Colon [26, 31]. The
Colon 26 and Colon 26—10 tumors were grown in female BALB/c mice
and the Colon 38 tumor, in female C57/B16 mice (Harlan/Olac, Zeist,
The Netherlands). The mice were kept in an area maintained on
a standardized light/dark cycle and had access to food (RMH-B
10 mm code 2100, Hope Farms, Woerden, The Netherlands) and
water ad libitum. Tumors were transplanted s.c. in both flanks in the
thoracic region in small fragments of 1—5 mm3. When tumors reach-
ed a volume of 50—150 mm3, treatment was started. Tumor size was
determined by caliper measurement (length]width]height]0.5)
twice a week, which was shown to be the most reliable method
[20, 29]. The volume of the tumors was expressed relative to that
determined on the 1st day of treatment (day 0). Before treatment,
mice were randomized into several groups, one group serving as
a control group and the others, as treatment groups. Each group
consisted of at least 6 mice, corresponding to 12 tumors. Antitumor
activity was evaluated by calculation of the T/C values, i.e., by
dividing the relative tumor volume of treated mice by that of the
control mice; the growth-delay factor (GDF) was defined as the
mean number of tumor-doubling times gained by treatment and was
calculated as the doubling time of treated tumors minus the doubl-
ing time of control tumors divided by the doubling time of controls.
The increase in life span (ILS) was calculated because mice bearing
Colon 26 suffer from cachexia when the tumor mass exceeds
500 mm3, leading to death of the mice. The reduction in cachexia
observed during gemcitabine treatment resulted in a prolonged life
span and was a parameter for the efficacy of the treatment. ILS was
defined as the median life span of the treated group divided by the
median life span of the control group times 100%, using the day of
transplantation as day 0. The day of death was defined as the day at
which mice were taken off the experiment when the cachexia-in-
duced weight loss was ’15% and was associated with a total
tumor volume of 800 mm3. Mice bearing Colon 38 tumors were
killed because of their tumor burden (’2, 000 mm3) . Differences in
significance between the antitumor effects of a particular treatment
were determined by means of Student’s t-test.
Doses and schedules
Mice were treated by i.p. bolus injection, s.c. continuous infusion
and i.v. continuous infusion. The maximal tolerated dose (MTD)
was assessed in non-tumor-bearing BALB/c and C57/B16 mice and
was defined as the dose that caused a maximal weight loss of 15%.
One part of the continuous-infusion studies was performed by giving
the drug s.c. with Alzet Micro-Osmotic Pumps (Alza Corporation,
Palo Alto, Calif. USA). The osmotic pumps were implanted s.c. and
delivered the drug for 3 or 7 days (models 1003D and 1007D,
respectively). Pumps were removed after 3 or 7 days, at the end of the
infusion. After their removal we checked whether the pumps were
empty by transferring them into a vial containing 0.9% NaCl and
measured an eventual gemcitabine release by high-performance
liquid chromatography (HPLC) using a lBondapack C
18
column
with Pic B, (Waters) in 15% methanol (final concentration of hep-
tane sulfonic acid 5 mM) at pH 3.1. Peaks were detected and quanti-
tated according to their absorption at 254 and 280 nm. The deter-
mined postinfusion release was within the margins reported by
Alzet ( 5%).
Continuous i.v. infusion was performed via the tail vein. The mice
were anesthesized (i.m.) with Hypnorm (dose 0.02 ml/mouse weigh-
ing 20 g) and laid on a water-heated bed. The tail vein was punctured
with a 21-gauge needle. A catheter (Intramedic polyethylene tubing,
medical formulation PHF; inside diameter 0.58 mm, outside dia-
meter 0.97 mm; Clay Adams) was inserted into the tail vein and
flushed with 0.9% NaCl. Both tail and catheter were splinted.
Catheter and splint were protected by a plastic tube. Each mouse
was put separately in one cage, which was put on a heated water bed
to prevent hypothermia. The catheter was connected to a syringe,
which was placed in an infusion pump. Each mouse received 1.2 ml
solution containing gemcitabine in 0.9% NaCl per 24 h. After the
24-h infusion the catheter was removed. In a control experiment to
check whether the catheters were inserted in the vein the right way,
diluted India ink was injected. After a few minutes the color of the
eyes and feet of the mouse became greyish. When the mouse was
killed and opened we observed that organs such as the liver and
spleen had become completely black, indicating that the infusion
was indeed i.v.
Treatment was initiated at day 10 (Colon 26 and Colon 26—10)
and day 19 (Colon 38) after transplantation. All protocols were
approved by the ethics committee for animal experiments of the Free
University of Amsterdam.
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Plasma concentrations of gemcitabine and dFdU
Plasma levels of gemcitabine and dFdU were determined in mice
injected i.p. with 120 mg/kg gemcitabine. For each time point, blood
was sampled from three mice by cardiac puncture. Blood samples
were collected in heparinized tubes containing tetrahydrouridine
(THU) to prevent deamination of gemcitabine to dFdU. The blood
samples were immediately centrifuged and the supernatant was
frozen and stored at !20 °C until analysis. During the continu-
ous infusions we also sampled blood at several time points (days
0, 1, 2, and 3) and determined the possible gemcitabine and dFdU
concentrations.
Gemcitabine and dFdU were extracted from the plasma by the
addition of 0.5 ml plasma to the internal standard deoxycytidine.
Subsequently, 2 ml isopropylalcohol was added and allowed to
stand for 5 min, after which 5 ml ethylacetate was added and the
suspension was mixed and centrifuged for 5 min at 4,000 rpm. The
supernatant was transferred to another tube and blown to dryness at
40°C under N
2
. Before analysis the pellet was dissolved in 250 l1
HPLC mobile phase. Compounds were injected onto an HPLC
system consisting of an Econosphere-5-NH
2
column (length 25 cm,
internal diameter 4.6 mm, pore size 5 lm), a Waters M-45 pump,
and a Waters fixed-wavelength detector (M-440) set at 254 and
280 nm. The mobile phase consisted of a cyclohexane/dich-
loroethane/methanol/water/acetic acid mixture (60/15/25/0.1/0.05,
by vol.) and the flow rate was 2 ml/min. Peak heights were measured
and the concentrations of the compounds were quantitated by
calculation of the ratio between deoxycytidine and dFdC/dFdU.
A calibration curve ranging from 10 to 1,000 ng/ml was obtained by
spiking normal plasma. The limit of quantitation was about 0.5 lM
for dFdC and dFdU.
Pharmacokinetic parameters were calculated with PC-NONLIN
software (SCI software) using a two-compartment model. The area
under the plasma concentration-time curve (AUC) was calculated
using the trapezoidal rule. Total clearance was calculated by divid-
ing the dose by the AUC.
Results
Bolus-injection schedules
Table 1 summarizes the experiments performed to de-
termine the MTDs of the various schedules. Schedule
2 (120 mg/kg gemcitabine q3d]4) was considered to be
the standard i.p. schedule. This schedule had previously
been shown to be the most active bolus i.p. schedule for
treatment of mice bearing various types of xenografts
[4, 5, 13]. With this schedule, weight loss in BALB/c
mice varied between the experiments but was not more
than 15%. The weight loss was usually acute and ob-
served at 1 day after treatment. On the 2nd day the
mice recovered completely from the treatment. In tu-
mor-bearing mice, toxic deaths were occasionally ob-
served with schedule 2 (Table 1). The weight loss for
C57/B16 mice was lower, which allowed a substantial
increase in dose intensity (Schedules 4, 5, 6, and 8).
In Table 2 the antitumor activities for all experi-
ments are summarized on schedule 2, Colon 26—10
(Fig. 1) was the most sensitive tumor and Colon 38, the
least sensitive (GDF 6.5 and 0.9, respectively). Al-
though in C57/B16 mice the dose could be increased to
300 mg/kg (schedule 6; Fig. 2), this hardly improved the
antitumor activity (GDF 1.7). Since in Colon 26—10,
Table 1 Determination of the MTD of gemcitabine for various
schedules of administration!
Number Schedule Route Toxicity
MWL" Deaths
(%) (day) (n) (day)
BALB/c:
1 100 mg/kg (q3d]4) i.p. 12 (8) 0/5%
2 120 mg/kg (q3d]4) i.p. 10 (8) 6/36#,% (9)
3 150 mg/kg (q3d]4) i.p. 15 (10) 0/3$
4 180 mg/kg (q3d]4) i.p. 27 (13) 1/3$ (11)
5 240 mg/kg (q3d]4) i.p. 25 (10) 2/3$ (10)
7 100 mg/kg (q3d]6) i.p. 11 (8) 0/6%
9 2 mg/kg/24 h
(3d pump) s.c. 11 (6) 2/10% (3)
10 3.5 mg/kg/24 h
(3d pump) s.c. 24 (4) 5/5$ (4)
12 2 mg/kg/24 h
(7d pump) s.c. 20 (7) 5/5$ (7)
13 5 mg/kg/24 h
(q7d]2) i.v. 4 (2) 0/3$
14 10 mg/kg/24 h
(q7d]2) i.v. 9 (2) 0/3$
15 15 mg/kg/24 h
(q7d]2) i.v. 16 (5) 0/12%
C57/B16:
2 120 mg/kg (q3d]4) i.p. 4 (7) 0/12#
4 180 mg/kg (q3d]4) i.p. 8 (7) 0/3$
5 240 mg/kg (q3d]4) i.p. 4 (7) 0/3$
6 300 mg/kg (q3d]4) i.p. 4 (7) 1/6% (9)
8 120 mg/kg (q3d]6) i.p. 4 (6) 0/6%
9 2 mg/kg/24 h
(3d pump) s.c. 0 (1) 0/4%
11 1 mg/kg/24 h
(7d pump) s.c. 4 (6) 0/4%
12 2 mg/kg/24 h
(7d pump) s.c. 8 (11) 0/4%
15 15 mg/kg/24 h
(q7d]2) i.v. 9 (9) 0/3$
16 20 mg/kg/24 h
(q7d]2) i.v. 6 (8) 0/6%
17 25 mg/kg/24 h
(q7d]2) i.v. 18 (9) 0/3$
! Initial dosing studies were performed in BALB/c mice because of
the generally higher toxicity; the MTD was subsequently used as
a starting point for C57/B16 mice
"Maximal weight loss (%) as compared with the 1st day of treat-
ment (day 0), including the day after first treatment at which this was
observed
#Toxic deaths were found only in tumor-bearing mice
$Only non-tumor-bearing mice
% tumor-bearing and non-tumor-bearing mice
regrowth of the responding tumors was observed after
the last i.p. treatment, the number of injections was
increased, although the dose had to be decreased to
100 mg/kg gemcitabine (schedule 7). The antitumor ac-
tivity of this schedule, with similar toxicity, was signifi-
cantly better than that of the standard treatment
(P(0.01; GDF 9.6 and 6.5, respectively). The ILS was
also longer for mice that had been treated six times
than for those that had been treated four times.
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Table 2 Summary of the antitumor activity of gemcitabine given at various doses and schedules.
Schedule Schedule Exp- Route Antitumor effect
number
Dt! GDF" Max T/C# CR ILS$
(days) (day)
Colon 26:
Control 2.8
2 120 mg/kg (q3d]4) 1 i.p. 13.2 & 5.1 0.63* (3) 0/8 264
9 2 mg/kg/24 h (3d pump) 2 s.c. 9.8 & 2.2 0.35+ (6) 0/5 135
15 15 mg/kg/24 h (q7d]2) 3 i.v. 8.7 & 2.8 0.29+ (2) 0/5 173
2 120 mg/kg (q3d]4) 4 i.p. 16.7& 3.6 0.25+ (8) 0/7 167
15 15 mg/kg/24 h (q7d]2) 4 i.v. 14.6 & 3.0 0.59* (12) 1/6 167
Colon 26-10:
Control 2.8
2 120 mg/kg (q3d]4) 1 i.p. 20.1 & 6.7 0.02+ (10) 1/9 144
2 120 mg/kg (q3d]4) 2 i.p. 21 & 6.5 0.03+ (11) 1/7 159
1% 100 mg/kg (q3d]4) 2 i.p. 22.6 & 7.1 0.03+ (11) 2/10 156
7 100 mg/kg (q3d]6) 2 i.p. 29.7 &,' 9.6 0.02+ (18) 1/10 207
9 2 mg/kg/24 h (3d pump) 3 s.c. 8.4 & 1.5 0.27, (6) 0/5 100
2 120 mg/kg (q3d]4) 4 i.p. ’36 & 6.1 0.041+ (10) 3/13 163
15 15 mg/kg/24 h (q7d]2) 4 i.v. 20.7 & 13.6 0.044+ (14) 4/11 242
2 120 mg/kg (q3d]4) 5 i.p. 19.6 & 6.5 0.025+ (10) 0/9 216
15 15 mg/kg/24 h (q7d]2) 5 i.v. 48.6 &,) ’17.7 0.007+ (14) 8/11 ’1, 000.
Colon 38:
Control 7.5
2 120 mg/kg (q3d]4) 1 i.p. 16.6 & 0.9 0.29, (17) 0/8
2 120 mg/kg (q3d]4) 2 i.p. 14.7 & 1.1 0.29, (9) 0/8
8 120 mg/kg (q3d]6) 2 i.p. 18& 1.5 0.18* (16) 0/8
6 300 mg/kg (q3d]4) 2 i.p. 19.3& 1.7 0.10, (9) 0/8
9 2 mg/kg/24 h (3d pump) 3 s.c. 10.8& 2.4 0.49* (12) 0/5
12 2 mg/kg/24 h (7d pump) 3 s.c. 10.3& 2.3 0.27, (8) 0/6
16 20 mg/kg/24 h (q7d]2) 4 i.v. 9.3 0.4 0.52, (14) 0/7
!Mean doubling time of tumors
"GDF"(doubling time of treated tumors - doubling time of control tumors)/doubling time of controls. Values of ’1 indicate that the
tumor is sensitive
#T/C"relative tumor volume of treated animals/relative tumor volume of controls
$ ILS"Median life span of the treated group/median life span of the control group ]100%, using the day of transplantation as day 0
% 100 mg/kg q3d]4 was included to provide a direct comparison with 100 mg/kg q3d]6
Doubling-time statistics:
&Significantly different from control tumours (P(0.001)
' 100 mg/kg q3d]6 significantly different from 100 mg/kg q3d]4 (P(0.01)
)15 mg/kg/24 h q7d]2 significantly different from 120 mg/kg q3d]4 (P(0.001)
Tumor-volume statistics:
*Significantly different from control tumors (P(0.05)
+Significantly different from control tumors (P(0.001)
,Significantly different from control tumors (P(0.01)
-Arbitrary numbering of separate experiments
. since most mice were cured, exact ILS could not be determined
CR complete remission
Continuous-infusion doses and schedules
The initial doses for the continuous infusions were
based on the ratio between the IC
50
values determined
for 1 and 48 h. Additionally, it had been observed
earlier that more frequent administration (once daily)
necessitated a considerable decrease in the dose. In the
experiments in which BALB/c mice were treated with
the s.c. osmotic pumps, the MTD for a 3-day infusion
was 2 mg/kg gemcitabine per 24 h (schedule 9); for the
7-day infusion, 2 mg/kg per 24 h (schedule 12) was well
above the MTD (20% weight loss; Table 1). The toxi-
city observed in BALB/c mice bearing Colon 26—10
and treated for 3 days was comparable with that of the
i.p. 120 mg/kg q3d]4 (schedule 2) treatment. The anti-
tumor activity (Table 2), however, was lower. For Co-
lon 26-bearing animals (Fig. 3) the toxicity of the 3-day
infusion (schedule 9) was also comparable with that of
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Fig. 1 Antitumor activity against Colon 26-10 of dFdC given at
several schedules and doses. Tumor volumes are depicted as mean
values$SEM (Circles Control growth [SEM are within the sym-
bols], squares i.p. 120 mg/kg dFdC q3d]4, inverted triangles i.p.
100 mg/kg q3d]6, triangles continuous infusion 15 mg/kg per 24 h
q7d]2). The curves generated for the treatments derive from separ-
ate experiments, in which the control tumors grew at a comparable
rate. At day 14, 15 mg/kg per 24 h q7d]2 was significantly different
from 120 mg/kg q3d]4 (P(0.05)
Fig. 2 Antitumor activity against Colon 38 of dFdC given at several
schedules and doses. Tumor volumes are depicted as mean
values$SEM (Circles Control growth, squares i.p. 120 mg/kg
dFdC q3d]4, white inverted triangles i.p. 120 mg/kg q3d]6, dia-
monds i.p. 300 mg/kg q3d]4, black triangles continuous infusion
20 mg/kg per 24 h q7d]2). The curves generated for the treatments
derive from separate experiments, in which the control tumors grew
at a comparable rate. At day 9, 300 mg/kg q3d]4 was significantly
different from 120 mg/kg q3d]4 (P(0.01) ; at day 8, 2 mg/kg per
24 h (7-day pump) was not significantly different from 2 mg/kg per
24 h (3-day pump)
the 120 mg/kg q3d]4 schedule (schedule 2), and, as in
Colon 26—10, schedule 9 was less effective than the
i.p. treatment (schedule 2). The MTD in C57/B16 mice
was higher than that in BALB/c mice (Table 1). A sig-
nificantly better antitumor effect was obtained for
Fig. 3 Antitumor activity against Colon 26 of dFdC given at several
schedules and doses. Tumor volumes are depicted as mean
values$SEM. (Circles Control growth, squares i.p. 120 mg/kg
dFdC q3d]4, white triangles continuous infusion s.c. 2 mg/kg per
24 h for 3 days, black triangles continuous infusion i.v. 15 mg/kg per
24 h q7d]2). The curves generated for the treatments derive from
separate experiments, in which the control tumors grew at a compa-
rable rate. At day 8, 120 mg/kg q3d]4 was not significantly different
from 15 mg/kg per 24 h q7d]2
Colon 38 with both s.c. infusion schedules (3 days
[schedule 9] and 7 days [schedule 12] ) than with the
i.p. treatment (P(0.05; GDF 2.4, 2.3, and 0.9, respec-
tively). All tumors started to regrow after discontinu-
ation of the treatment.
The MTD for a 24-h i.v. infusion of gemcitabine in
BALB/c mice appeared to be 15 mg/kg per 24 h (sched-
ule 15) and that in C57/B16 mice, 20 mg/kg per 24 h
(schedule 16) when treatment was repeated after 1 week
(Table 1). The highest weight loss was found after
3 days, but the mice recovered before the next infusion.
Again, for Colon 26 tumors the 24-h infusion gave
results comparable with those of the 3-day continuous
infusion. Against Colon 38 this 24-h infusion was less
effective than the i.p. and 3-day continuous-infusion
treatment. Against Colon 26—10, however, the
15 mg/kg per 24 h q7d]2 i.v. gemcitabine schedule
(schedule 15) was superior to any other treatment
(P(0.001; GDF ’17.7) as observed in several separ-
ately performed experiments. No direct regrowth was
observed after cessation of the i.v. treatment, in con-
trast to the i.p. schedules; the ILS showed a marked
increase.
Plasma concentrations of gemcitabine and dFdU
Plasma concentrations of gemcitabine were determined
at the various administration schedules. For the
bolus injections the plasma peak concentration of
gemcitabine was 225 lM as determined at 10 min
after injection, the peak for dFdU (79 lM) was
339
Fig. 4 Plasma concentrations of gemcitabine (circles) and dFdU
(squares) as determined after one bolus injection of 120 mg/kg dFdC.
Data represent mean values$SEM
observed at 30 min (Fig. 4). The elimination half-lives
of gemcitabine and dFdU were 15.7 min and 8.2 h,
respectively. The clearance calculated for gemcitabine
was 1.68 ml/min, but that found for dFdU was 3 times
lower. The AUC determined after one bolus injection of
gemcitabine was 7,587 lmolmin 1~1. A doubling of the
dose resulted in a 2-fold increase in the AUC
(14,917 lmolmin l~1) without affecting half-lives or
elimination. At a weekly interval, 240 mg/kg is the
MTD. Plasma concentrations measured for gem-
citabine and dFdU after continuous infusions were
below the detection limit.
Discussion
This study is the first to demonstrate that continuous
infusions of gemcitabine can significantly improve its
antitumor effect against solid tumors. From previous
studies the antitumor effect of gemitabine was known
to be strongly schedule-dependent, but no continuous-
infusion schedules were tested [5, 6, 8, 13, 27]. The i.p.
schedule of 120 mg/kg q3d]4 (schedule 2) was very
effective, but we now show that either an increase in the
dose (schedule 6) or prolongation of the treatment
(schedules 7 and 8) can result in a better effect.
In patients the schedule most often applied is a 30-
min infusion of 800—1,250 mg/m2 q7d]3, followed by
a 1-week rest period. On this weekly schedule, pro-
nounced activity has been observed against several
tumor types, such as ovarian and non-small-cell lung
cancer [1, 14, 17]. However, other frequently applied
antimetabolites such as 1-b-D-arabinofuranosyl-
cytosine and methotrexate are usually given over lon-
ger periods, since it has been shown that this provides
optimal efficacy [22, 24]. For 5-fluorouracil, adminis-
tration as a continuous infusion increased the response
rate, although the survival of patients was not improved
[16, 22]. Also for gemcitabine treatment we could
show in our model system that a prolongation of the
treatment (schedules 7 and 8) or continuous infusions
(schedules 12 and 15) could result in a better effect.
A major decrease in gemcitabine dosing was observed
when the drug was given for prolonged periods. For i.p.
scheduling a more frequent administration led to sim-
ilar observations (a lower gemcitabine dose) in earlier
preclinical [5, 6, 8] and clinical studies [17]. The anti-
tumor activity, however, did not increase. This may be
explained by a lower accumulation of dFdCTP, the
active metabolite of gemcitabine, in the tumors. How-
ever, Grunewald et al. [10] showed that with prolonga-
tion of the infusion time from 30 to 60 min, at total dose
of 800 mg/m2 the cellular AUC of dFdCTP in blast
cells increased by up to 4 orders of magnitude. In an
additional clinical study the infusion times were pro-
longed further; unfortunately, the response rate was not
increased [11]. Both studies, however, were performed
in leukemia patients. Since solid tumors seem to re-
spond better to gemcitabine treatment than do
leukemias, application of these prolonged infusion
schedules to patients with solid tumors, is warranted,
also considering the results we obtained in murine
colon tumors. In a recent phase I trial applying con-
tinuous infusions the MTD for a 24-h infusion was
180 mg/m2 [3], which is 5—10 times lower than the
MTD for the now frequently used weekly bolus-injec-
tion schedule [14, 17]. A similar ratio was noted in our
studies. It would be worthwhile to test continuous-
infusion schedules in more tumor types because when
cells are exposed to gemcitabine over a longer period
there is a more effective dFdCTP formation and the
total retention of dFdCTP is probably longer lasting
[26] ; thus, one can expect a better therapeutic effect of
the drug. It might even be considered to evaluate 24-h
infusions in insensitive tumor types such as colon can-
cer. Another application for continuous infusions
would be the combination of gemcitabine with other
agents, similar to that of other antimetabolites with,
e.g., cisplatin [4, 19, 28].
There seems to be a threshold for gemcitabine to be
active as shown in in vitro studies. In vitro, IC
50
values
for gemcitabine drop dramatically with extension of the
exposure period, an effect that is most pronounced in
colon-tumor cell lines [26]. In C26-10 cells derived
from the Colon 26 tumour, accumulation of dFdCTP,
the active metabolite of gemcitabine, was time- and
concentration-dependent. Thus, to obtain an optimal
therapeutic index for gemcitabine, it is extremely im-
portant that the optimal dose be chosen in combina-
tion with the best infusion time and dosing interval.
From our results it appears that high doses given by
bolus injection at longer intervals are best tolerated by
normal tissue, whereas for a good antitumor effect
a more prolonged infusion seems most promising. To
enable the choice of the right schedule, more research is
needed on the toxicity patterns of the i.p. schedule as
compared with prolonged infusions.
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The pharmacokinetic parameters of gemcitabine and
dFdU in the mouse (i.p. schedule) and in humans (a
30-min infusion given every week for 3 weeks, followed
by 1 week of rest) are of the same order of magnitude as
those found in our mice [11, 22]. In humans the elimi-
nation from plasma mainly involved dFdU, the
deamination product of gemcitabine. The elimination
of gemcitabine was rapid (t
1@2
8 min) as compared
with that of dFdU (t
1@2
14 h). In both species the
peak concentration of dFdU was observed much
later than that of gemcitabine and dFdU was retained
much longer than gemcitabine. The AUC value
obtained at the weekly MTD (240 mg/kg) in mice
is comparable with that achieved in humans
treated at 3-weekly intervals (16,968 lmolmin l~1 at
5,700 mg/m2) [22].
Mechanisms that may be involved in the difference in
sensitivity to gemcitabine could be the activities of the
activating and inactivating enzymes deoxycytidine
kinase (dCK) and deoxycytidine deaminase (dCDA). In
all tumors tested, dCK activity was high enough (data
not shown) to activate gemcitabine and there was no
correlation between the dCK and dCDA activity and
the sensitivity [25]. Another possibility involved in the
difference in sensitivity may consist of the difference in
the mouse strain used; higher doses could be given to
C57/B16 mice. The differences between the tumors may
have contributed to the various sensitivity profiles.
Colon 38 is a necrotic tumor with a relatively long
doubling time, which may explain why relatively long
infusions seem more active. Under these conditions,
less dFdCTP may be formed, but since the exposure is
long, this may be sufficient to obtain an enhancement
of the antitumor effect similar to that achieved by
long-term exposure in vitro [26]. Colon 26—10, how-
ever, is much less necrotic, does not cause cachexia, and
is the most sensitive tumor. This tumor is fast-growing,
which may explain why bolus injections and relatively
short infusions are more effective; higher peak dFdCTP
levels can be formed, causing more damage to the
fast-growing cells. Colon 26 causes cachexia but is not
necrotic. Treatment with gemcitabine apparently re-
duces the incidence of cachexia, because these mice
remain in good condition. This may be related to the
increase in adenosine triphosphate (ATP) pools ob-
served following treatment with gemcitabine [26].
Relatively high peak levels of dFdCTP may be required
for this.
In conclusion, prolonged infusions of gem-
citabine can considerably improve the antitumor activ-
ity of the drug against solid tumors and may provide
a valuable tool for the treatment of (insensitive) solid
tumors.
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